. W e evaluated 20 healthy volunteers, 10 of which received a single oral dose of midazolam (15 mg, one tablet) and 10 of which received placebo, in a double-blind design. Tablets were administered at 2200 h, bedtime. On the following day, all subjects were submitted to a clinical evaluation, a subjective checklist and the MSLT. The mean age was 34.7^ 8.9 years in the midazolam and 38.0+ 10.6 years in the placebo groups (n.s.). Sex and weight distributions were similar in both groups (n.s.). Clinical evaluation and subjective symptom checklist did not make evident significant differences between midazolam and placebo groups (n.s.). The MSTL was performed at 0900, 1100, 1300, 1500 and 1700 h. Mean sleep latencies were 12.0, 12.7, 8.0, 13.5, 17.0 min in the midazolam group; mean sleep latencies were 13.8, 9.0, 6.9, 9.5, 13.6 min in the placebo group (n.s.). In the single dose, double-blind design here evaluated, midazolam did not show differences in relation to placebo on the following day, detectable by the MSLT. (MSLT) 2 »3,i6,20 is an objective, standardized, quantitative and reliable tool for the daytime sleepiness evaluation.
The present study was designed to address the possibility of daytime sleepiness using the MSLT after ingestion of midazolam as a hypnotic, at bedtime.
METHODS
The subjects were 20 healthy volunteers. 10 of which received a single oral dose of midazolam (15 mg, one tablet) and 10 received a placebo, in a double-blind paradigm. Mida zolam and placebo tablets were identical in appearance. The tablets were administered at bedtime, which was fixed at 2200 h. On the following day, all subjects were submitted to the MSLT, clinical evaluation and symptom checklist. (Fisher test, p>0.05, n.s.) .
The MSLT was applied using the standardized technique recommended by Carskadon & col. 2,3,16. This test was performed allowing the subject to sleep, at 2 h intervals, starting at 0900 h, for a total of 5 consecutive times, that is at 0900, 1100, 1300, 1500 and 1700 h. The test was conducted at the Sleep Disorders Center in a pleasant bedroom, which is lightproofed, sound-attenuated, controlled at a constant temperature (21©C) and furnished with a comfortable bed. As the objective of the test was to quantify the tendency to sleep, any external factor that could impair the results w a s avoided. The subjects wore comfortable everyday clothes. During the intervals between tests they stayed out of the bedroom and did not sleep. (Table  1 ). In the placebo group, mean sleep latencies were 6.9-13.6 min. There were no significant differences between both groups (Mann-Whitney test, n.s.). Stage REM occurred in only one subject, from the placebo group, at 1300 h; it was not present in the midazolam group.
COMMENTS
The MSLT is an objective and quantitative way of evaluating the degree of daytime sleepiness. It is used to verify the impairment of excessive daytime sleepiness patients, including those with sleep apnea, narcolepsy, periodic limb movement disorder, and depression. It is also employed to differentiate between the complaint of fatigue and sleepiness, which may be difficult at times, based exclusively on patients reports. The MSLT has been also used in the evaluation of daytime alertness impairment due to sleep deprivation, and in that secondary to hypnotics ingestion at bedtime 19, In the present study, a single oral dose of midazolam (15 mg) or placebo were administered to healthy subjects at bedtime, in a double-blind design. The subjective evaluation by the clinician) as well as by the subjects checklist did not demonstrate significant differences between midazolam and placebo groups. The absence of subjective residual effects of this drug has been reported in several publications 4,10,12,18.
The MSLT, as an objective tool, did not show significant differences between midazolam and placebo in our sample. This finding may be attributed to its ultrashort half-life of 1.9 ± 0.4 h with recommended dose range of 7.5 -15.0 mg 4,6,7,11,13-15^ and the absence of significant long acting metabolites. Our data agree with the lack of residual effects 7 or more hours after midazolam administration described in other publications using such distinct objective tools as the digit symbol substitution test 1 2 , complex reaction time task 1 2 , body sway 8 >9, choice reaction times, critical flicker thresholds, and auditory evoked responses 9.
The tendency iot shorter sleep latencies detected in the early afternoon, which was present in the midazolam group, as well as in the placebo group, corresponds to the well documented semicircadian pattern of sleepiness oscilation observed in normal subjects Aknowledgement -W e thank K.N. Salomão for statistical advice and support.
